论文部分内容阅读
ＦＤＡ批准格雷色隆史克·比切公司的５ＨＴ３拮抗剂，具有镇吐作用的格雷色隆（注射剂，商品名Ｋｙｔｒｉｌ）已获ＦＤＡ批准。该药已在日本和许多欧洲国家上市。１９９３年初，ＦＤＡ的胃肠药物顾问委员会因该品存在安全性问题，即有致癌作用和心血管副作用，而驳回了该...
The FDA approved the 5HT3 antagonist from GlaxoSmithKline Biche and the grenadine (injection, Kytril) with antiemetic action has been approved by the FDA. The drug is available in Japan and many European countries. In early 1993, the FDA’s Gastrointestinal Medicine Advisory Board rejected the safety issue due to the product’s carcinogenic and cardiovascular side effects ...